Stocks · News reference
BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beeline Medicines Corporation announced Phase 2 study results for afimetoran, an investigational TLR7/8 inhibitor originally discovered by Bristol Myers Squibb.
Bloomsbury Publishing has announced it will publish 'Dancing Through Life: A Broadway Memoir of Luck & Talent' by Larry Fuller in May 2027.
Aberdeen Group plc has notified Bloomsbury Publishing plc that its voting rights in the company have fallen below the 5% threshold.
Bristol Myers Squibb has triggered a clinical development milestone payment to Editas Medicine, as reported in the latter's third-quarter 2026 financial update.
Contineum Therapeutics has updated its ongoing Phase 2 clinical trial for idiopathic pulmonary fibrosis by adding an imaging-based assessment criterion.
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.